PRLD
NASDAQ HealthcarePrelude Therapeutics Incorporated - Common Stock
Biotechnology
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
๐ Market Data
| Price | $5.63 |
|---|---|
| Volume | 262,283 |
| Market Cap | 448.40M |
| Beta | 0.940 |
| RSI (14-Day) | 72.1 Overbought |
| 200-Day MA | $3.30 |
| 50-Day MA | $4.53 |
| 52-Week High | $5.91 |
| 52-Week Low | $0.83 |
| Forward P/E | -7.51 |
| Price / Book | 4.33 |
๐ฏ Investment Strategy Scores
PRLD scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (85/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ช Falling Knife (3/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find PRLD in your text
Paste any article, transcript, or post โ the tool will extract PRLD and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-08-17.